Effects of IL-17A Inhibition on Idiopathic Subglottic Stenosis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• diagnosis of idiopathic subglottic stenosis
Locations
United States
Connecticut
Yale New Haven Hospital
RECRUITING
New Haven
Contact Information
Primary
Nwanmegha Young, MD
Nwanmegha.Young@yale.edu
(203) 737-1140
Time Frame
Start Date: 2025-02-20
Estimated Completion Date: 2026-04
Participants
Target number of participants: 10
Treatments
Experimental: Talz
All participants receive Talz
Related Therapeutic Areas
Sponsors
Collaborators: Lilly PharmaceuticalCompany
Leads: Yale University